GNPX - Genprex, Inc.
| Previous Close | 0.9524 |
| Open | 0.9640 |
| Bid | 0.9200 x 1300 |
| Ask | 1.3000 x 1100 |
| Day's Range | 0.9200 - 0.9688 |
| 52 Week Range | 0.6410 - 2.7500 |
| Volume | 22,170 |
| Avg. Volume | 39,845 |
| Market Cap | 15.268M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7550 |
| Earnings Date | Apr 1, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.25 |
- GlobeNewswire
Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Company’s Milestone Achievements
NEW YORK, Aug. 22, 2019 -- via NetworkWire -- Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted.
- Simply Wall St.
What Kind Of Investor Owns Most Of Genprex, Inc. (NASDAQ:GNPX)?
A look at the shareholders of Genprex, Inc. (NASDAQ:GNPX) can tell us which group is most powerful. Insiders often own...
- Business Wire
Genprex to Present at the RHK Capital 4th Annual Disruptive Growth Conference
Genprex, Inc. , a clinical-stage gene therapy company, today announced that its Chairman and Chief Executive Officer, Rodney Varner, is scheduled to present at the 4th Annual Disruptive Growth Conference hosted by ReedSmith in New York City on September 4, 2019.
- Business Wire
Genprex Demonstrates Growth and Expansion Through Recent Achievements
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced recent achievements the company has completed as a part of the company’s overall strategy to expand its clinical development programs and bring its lead drug candidate, Oncoprex™ immunogene therapy, to commercialization. “Since Genprex’s IPO last year, we have made significant progress in many areas of the company, including progress toward expansion of our clinical programs and sponsored research, our manufacturing process development and scalability, and the growth of our team to support these initatives,” said Rodney Varner, Chairman and Chief Executive Officer of Genprex.
- Business Wire
Genprex™ Manufacturing Partner Aldevron Completes Significant Step in Manufacturing for Oncoprex™ Clinical Development Program
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, announced that its manufacturing partner, Aldevron, has successfully completed the manufacturing of the TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA pursuant to the manufacturing agreement between Genprex and Aldevron that was announced in September 2018. Genprex’s initial product candidate, Oncoprex™ consists of a TUSC2 plasmid DNA manufactured by Aldevron encapsulated in a nanovesicle made from lipid molecules with a positive electrical charge.
- Business Wire
Genprex Begins Next Phase of Drug Branding Program
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced it has initiated the first phase of branding its lead drug candidate, Oncoprex™ immunogene therapy, and has completed the creation and submission of non-proprietary drug name selections to the American Medical Association’s United States Adopted Names (USAN) Council.
- GuruFocus.com
5 Immunotherapy Stocks to Keep a Close Eye On
Immunotherapy is changing the face of cancer treatment as we know it, creating compelling investment opportunities
- Business Wire
Genprex Provides Update on Development of its Oncoprex Immunogene Therapy in Combination with Immunotherapy for Non-Small Cell Lung Cancer
Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company, today provided an update on development of its lead drug candidate, Oncoprex™ immunogene therapy, in combination with immunotherapy for the treatment of non-small cell lung cancer (NSCLC). In July 2018, the company entered a Sponsored Research Agreement with The University of Texas MD Anderson Cancer Center (“MD Anderson”) to fund a research study entitled, “A Novel Therapeutic Approach for the Treatment of Cancer Using a Combination of the Multifactorial Tumor Suppressor Gene TUSC2 and Immunotherapy.” The TUSC2 gene is the active agent in Genprex’s Oncoprex immunogene therapy.
- GlobeNewswire
Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Gene Therapy as Potential Cancer Treatment
Preliminary results show that Oncoprex has the potential to become an effective add-on therapy for the treatment of deadly non-small cell lung cancer. Genprex Inc. (GNPX) plans to expand the current erlotinib-Oncoprex trial to multiple research centers and conduct more new trials. If Phase II results are as positive as preliminary indications, it could spark a rally in the shares and possibly even lure a large biotechnology or pharma company to sign a high-value partnership with Genprex.
- GlobeNewswire
Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Hunt for Gene Therapy Breakthroughs
NEW YORK, May 30, 2019 -- via NetworkWire — Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted.
- Business Wire
Genprex to Present at Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced it will be presenting at the upcoming Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum at the Waldorf Astoria Chicago on May 31, 2019. Taking place on the first day of ASCO, the 5th Annual Immuno-Oncology BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment. Genprex will be among the 30+ presentations by listed and private biotechnology companies at the event.
- GlobeNewswire
Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Promising New Gene Therapies
Gene therapies, the promising treatments pursued by companies such as Genprex Inc. (GNPX), are based on turning [the] problem [of cell mutation] on its head. Once in place, successful gene therapies replace damaged or missing code and help the body cure itself. Creating these treatments is challenging work, and the companies that excel are innovators with the ability to try new approaches.
- GlobeNewswire
Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Gene Therapies for Cancer Treatment
NEW YORK, May 08, 2019 -- via NetworkWire — Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted.
- Business Wire
Genprex Retains Addison Whitney for Drug Nomenclature Branding
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that it has taken a significant step toward commercialization of its lead drug candidate by retaining the services of leading pharmaceutical branding agency, Addison Whitney. Addison Whitney, a Syneos Health company, will draw from its 28-year history to oversee the proprietary and non-proprietary drug naming process for Genprex’s lead drug candidate, currently known as Oncoprex™ immunogene therapy, for non-small cell lung cancer. Oncoprex immunogene therapy has shown promise in targeting and treating non-small cell lung cancer (NCSLC) through its proprietary technology platform, which transports cancer-fighting genes to cancerous cells by encapsulating the genes into nanoscale hollow spheres, called nanovesicles, which are then administered intravenously.
- Newsfile
Genprex Featured in NetworkNewsAudio Broadcast on Potential Gene Therapy Treatment for Cancer
New York, New York--(Newsfile Corp. - April 12, 2019) - Genprex Inc. (NASDAQ: GNPX) announces the availability of a NetworkNewsAudio broadcast titled, "Potential Blockbuster Gene Therapy Programs to Watch in 2019."To hear the NetworkNewsWire Audio version, visit: http://nnw.fm/j1WMsTo read the full editorial, visit: http://nnw.fm/YC9iqGenprex already has over 30 issued patents for its platform technologies. The company's promising pipeline currently includes a phase I/II clinical trial underway to evaluate intravenous Oncoprex immunogene therapy in ...
- GlobeNewswire
Genprex (GNPX) Featured in NetworkNewsAudio Broadcast Discussing Gene Therapy Programs on the Cusp of Curing the Incurable
The company’s promising pipeline currently includes a phase I/II clinical trial underway to evaluate intravenous Oncoprex immunogene therapy in combination with another cancer drug, Tarceva, and pre-clinical research of the combination of Oncoprex immunogene therapy with immunotherapies. Gene therapy programs may be on the cusp of curing the incurable, and the companies that deliver these medical miracles are in an ideal position to reap a bonanza of recognition and rewards. Given the promise of Genprex’s pipeline of cancer killers with global blockbuster potential, the company certainly appears to be one to watch.
- Newsfile
Genprex (GNPX) Featured in NetworkNewsWire Publication about Revolutionary Gene Therapies
New York, New York--(Newsfile Corp. - April 11, 2019) - Genprex Inc. (NASDAQ: GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities.To view the full publication, titled "Potential Blockbuster Gene Therapy Programs to Watch in 2019," visit: http://nnw.fm/YC9iqPerhaps no other disease strikes as much dread and fear as cancer. Many successful treatments are available today that didn't exist just ...
- GlobeNewswire
Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Cancer and Gene Therapy Treatment
NEW YORK, April 11, 2019 -- via NetworkWire — Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted.
- Business Wire
Genprex Collaborators Report Positive TUSC2 and Checkpoint Blockade Preclinical Data at the 2019 AACR Annual Meeting
TUSC2 Immunogene Therapy Overcomes Resistance to Checkpoint Blockade
- Business Wire
Genprex Provides Clinical, Corporate, and Financial Update for the Year Ending December 31, 2018
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced a clinical and corporate update and the filing of financial results for the year ended December 31, 2018 on Form 10-K with the United States Securities and Exchange Commission. “Over the past year, we made great progress in advancing the development of our gene therapy platform, including Oncoprex™ immunogene therapy for non-small cell lung cancer,” said Rodney Varner, Chairman and Chief Executive Officer of Genprex. “I’m pleased with our progress and am excited to continue development of our gene therapies for cancer into 2019 and beyond.
- Newsfile
Genprex Featured in NetworkNewsAudio Publication on Unprecedented Targeting in Cancer Treatment
New York, New York--(Newsfile Corp. - March 29, 2019) - Genprex Inc. (NASDAQ: GNPX) announces the availability of a NetworkNewsAudio publication titled, "Advanced Medical Technologies Provides Unprecedented Targeting in Cancer Therapy."To hear the NetworkNewsWire Audio version, visit: http://nnw.fm/XRt4dTo read the full editorial, visit: http://nnw.fm/tB7LiA multiplicity of potential breakthrough treatments to fight cancer are in varying stages of clinical development, and many are focused on the promise of advanced gene therapies. Genprex Inc. (NASDAQ: ...
- GlobeNewswire
Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Advanced Medical Cancer Therapy
A multiplicity of potential breakthrough treatments to fight cancer are in varying stages of clinical development, and many are focused on the promise of advanced gene therapies. Genprex Inc. (GNPX) (GNPX Profile) is working to bring its potentially life-changing immunogene therapy, Oncoprex, to market. Genprex already has 30 issued patents for its platform technologies and gene therapies.
- GlobeNewswire
Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Innovative Cancer Treatments
NEW YORK, March 28, 2019 -- via NetworkWire — Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted.
- Newsfile
Genprex Featured in NetworkNewsWire Publication on Innovations in Cancer Therapy
New York, New York--(Newsfile Corp. - March 28, 2019) - Genprex Inc. (NASDAQ: GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities.To view the full publication, titled "Advanced Medical Technologies Provides Unprecedented Targeting in Cancer Therapy," visit: http://nnw.fm/l3DkVGenprex is on the cusp of potentially delivering life-changing therapeutics for cancer patients by utilizing the company's novel proprietary technology platform. ...
- GlobeNewswire
Genprex Inc. Discusses Plans to Expand Clinical Trials in Fight Against Cancer in Exclusive Audio Interview with NetworkNewsWire
NEW YORK, March 19, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community, today announces the online availability of its interview with Genprex Inc., a clinical stage gene therapy company developing a new approach to treating cancer. NNW’s Stuart Smith introduces Genprex CEO and Chairman Rodney Varner, JD, for a compelling discussion on the company’s initial product candidate, Oncoprex(TM), an immunogene therapy for non-small cell lung cancer (NSCLC). The American Cancer Society reports that NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancer.
